Allergy Therapeutics PLC (AIM:AGY, FRA:HHU) (LON:AGY) Head of Business Innovation Alan Bullimore to deliver the results of their successful primary outcome of the VLP-Peanut 001; a study evaluating biomarkers from peanut allergic patients.
Bullimore explains how they are using human blood samples through their collaboration with Imperial College London.
Findings now support the VLP Peanut first in-human Phase I study design which is on track to initiate in Q1 2022.
Bullimore also discusses the market, with the food allergy sector representing an $8bln opportunity worldwide.